Drug Maker Bests Q2 Forecasts After Hiking Prices on Dozens of Drugs in 2019 It’s that time again. Pharmaceutical companies are starting to report their earnings for Q2. Big Pharma giant Johnson & Johnson out of the gate Tuesday. The brand name drug maker announced better-than-expected second quarter earnings and raised its sales forecast for […]
Greater List Price Transparency Will Help Hold Big Pharma Accountable, Deter Price-Gouging Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today encouraging the U.S. House Committee on Energy & Commerce to advance the FAIR Drug Pricing Act being considered in a markup of over two dozen bills by the full […]
Drug Makers Continue Price-Gouging Patients as Americans Demand Accountability The summer is heating up and so too is Big Pharma’s zeal for putting profits over people. Brand name drug makers kicked off the mid-year months with price hikes on hundreds of drugs. Big Pharma’s summer price-gouging bonanza builds on the industry’s rapid pace of price […]
Decision to Sideline Misguided Proposal a Huge Win for America’s Seniors & Taxpayers, Loss for Big Pharma Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today reacting to the administration’s decision to withdraw a proposal from the Department of Health and Human Services (HHS) known as the Rebate Rule. “This decision […]
Senators Advance Three Measures to Help Lower Drug Prices as Momentum to Hold Drug Makers Accountable Builds Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement praising lawmakers on the U.S. Senate Committee on the Judiciary for advancing three important measures to crack down on anti-competitive tactics employed by Big […]
Advancement of CREATES and FAIR Drug Pricing Acts Marks Step Toward Boosting Competition and Transparency Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement praising lawmakers on the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee for taking up and advancing two bipartisan measures to boost competition and increase […]
This week, Big Pharma giant AbbVie announced plans to acquire drug maker Allergan in a $63 billion merger. AbbVie, the maker of top-selling drug in the U.S. Humira, notched over $32 billion in revenue in 2018, while Allergan, best known for manufacturing Botox, made nearly $16 billion in annual revenue. What do AbbVie and Allergan […]
Encourages Senate Panel to Further Strengthen Drug Price Package with REMEDY and FAIR Drug Pricing Acts Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today ahead of a U.S. Senate Health, Education, Labor and Pensions (HELP) Committee legislative markup of its drug pricing package, the “Lower Health Care Costs Act,” […]
Report Finds Significant Catastrophic Liability for Drug Makers Benefits Seniors, Taxpayers Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) said Tuesday that a new study from Oliver Wyman analyzing different cost sharing scenarios underscores the critical need to hold Big Pharma accountable in Medicare Part D reform. “Without more skin in the game, […]
Current Trade Agreement Could Hamper Generic and Biosimilar Competition Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) sent a letter to members of Congress today detailing concerns with the proposed U.S.-Mexico-Canada Agreement (USMCA) and asking lawmakers to address those concerns to protect American patients. “CSRxP believes that trade agreements are important tools to […]